Loading…
BioCardia, Inc. is projected to rise to $0.9317 by 2027, a +12% move from its current price of $0.8312. BCDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.7948 | $0.8317 | $0.8703 | +0.06% |
| Aug 6 | $0.7805 | $0.8323 | $0.8874 | +0.13% |
| Aug 7 | $0.7699 | $0.8328 | $0.9008 | +0.19% |
| Aug 8 | $0.761 | $0.8333 | $0.9124 | +0.25% |
| Aug 9 | $0.7534 | $0.8338 | $0.9229 | +0.32% |
| Aug 10 | $0.7466 | $0.8344 | $0.9324 | +0.38% |
| Aug 11 | $0.7405 | $0.8349 | $0.9414 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7405 | $0.8349 | $0.9414 | +0.45% |
| Week 2 | $0.7077 | $0.8386 | $0.9937 | +0.89% |
| Week 3 | $0.6843 | $0.8423 | $1.04 | +1.34% |
| Week 4 | $0.6656 | $0.8461 | $1.08 | +1.79% |
| Week 5 | $0.6498 | $0.8499 | $1.11 | +2.25% |
| Week 6 | $0.6362 | $0.8536 | $1.15 | +2.70% |
| Week 7 | $0.6242 | $0.8574 | $1.18 | +3.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioCardia, Inc. is a clinical-stage regenerative medicine company focused on cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate CardiAMP is an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
The company also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, BioCardia offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC.
BioCardia, Inc. is based in Sunnyvale, California.
BioCardia, Inc. (BCDA) currently trades at $0.8083 with a market capitalization of $12.03M and a rank of 4863 among listed equities. It sits in the Healthcare sector, reflecting its focus on regenerative medicine for cardiovascular and pulmonary conditions.
Technically, the stock shows a bearish near-term posture. The RSI14 is 40, and the price is below the SMA50 of $0.957 and the SMA200 of $1.20, with support at $0.80 and resistance at $1.24. The 30-day price range runs from $0.5716 to $1.14, underscoring notable volatility (annualized volatility is 100%).
Looking ahead, the year-by-year forecast outlines a path from 2026 through 2050 with distinct min/avg/max levels and ROI metrics. The 2026 average is $0.8083, and the later years show a transition from neutral to bullish momentum, with sizable upside potential by 2040 and especially by 2050 (avg $3.14, max $7.23; ROI 288.7%).
A major floor 43.1% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 49.2% above — a clean break opens room to run.
A major ceiling 70.0% above — clearing it would confirm fresh momentum.
Key BCDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.79 | Buy | $0.8054 | Buy |
| MA 10 | $0.844 | Sell | $0.8315 | Sell |
| MA 20 | $0.884 | Sell | $0.8773 | Sell |
| MA 50 | $0.9364 | Sell | $0.9485 | Sell |
| MA 100 | $1.05 | Sell | $1.04 | Sell |
| MA 200 | $1.18 | Sell | $1.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.92 | Neutral |
| Stoch RSI (14) | 61.79 | Neutral |
| CCI (20) | -63.68 | Neutral |
| Williams %R (14) | -66.67 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -6.82 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 33.33 | Neutral |
| TRIX (15) | -0.63 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 33.14 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.75 | Buy |
| ADX (14) | 19.93 | Neutral |
| ATR (14) | 0.04 | Info |
The near-term technical picture remains bearish, with sentiment labeled as BEARISH and RSI14 at 40. The price is trading below the SMA50 ($0.957) and the SMA200 ($1.20), and it sits near a support level of $0.80 with resistance at $1.24.
The 30-day range spans $0.5716 to $1.14, highlighting ongoing volatility. Investors should note the stock’s proximity to support and its sensitivity to short-term price movements in a thinly traded name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.77 | $0.8312 | $1.23 | 0% | Neutral | |
| $0.6987 | $0.9317 | $1.34 | +12% | Neutral | |
| $0.6291 | $0.8824 | $1.34 | +6% | Neutral | |
| $0.5847 | $0.8558 | $1.36 | +3% | Neutral | |
| $0.5008 | $0.7616 | $1.25 | -8% | Neutral | |
| $0.6105 | $0.9618 | $1.63 | +16% | Neutral | |
| $0.7404 | $1.21 | $2.10 | +45% | Bullish | |
| $0.7022 | $1.18 | $2.11 | +42% | Bullish | |
| $0.6764 | $1.17 | $2.15 | +41% | Bullish | |
| $0.6312 | $1.13 | $2.11 | +36% | Bullish | |
| $0.7732 | $1.59 | $3.24 | +91% | Bullish | |
| $1.44 | $3.20 | $7.36 | +285% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.77 | $0.8312 | $1.06 | +0.00% |
| September 2026 | $0.7483 | $0.9017 | $1.13 | +8.49% |
| October 2026 | $0.7223 | $0.8807 | $1.12 | -2.33% |
| November 2026 | $0.7142 | $0.8791 | $1.14 | -0.18% |
| December 2026 | $0.7556 | $0.9383 | $1.23 | +6.73% |
Click any year to see its month-by-month BCDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BCDA is projected to trade between $0.77 and $1.23, averaging $0.8312 — a potential gain of 0% from today's $0.8312. A consolidation phase looks the most probable path here.
BioCardia, Inc.'s 2027 outlook centres on $0.9317, within a $0.6987 to $1.34 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, BCDA could reach as high as $1.34, with a base case around $0.8824 and support toward $0.6291 — roughly +6% from $0.8312. A consolidation phase looks the most probable path here.
Expect BCDA to range from $0.5847 to $1.36 through 2029. The $0.8558 average target implies a +3% move from current prices. That is -3% versus the projected 2028 average. Price action looks broadly range-bound.
The BCDA price prediction for 2030 points to an average of $0.7616 (low $0.5008, high $1.25) — a potential decline of -8% on today's $0.8312. A consolidation phase looks the most probable path here.
In 2031, BCDA is projected to trade between $0.6105 and $1.63, averaging $0.9618 — a potential gain of +16% from today's $0.8312. That is up +26% on the projected 2030 average. Price action looks broadly range-bound.
BioCardia, Inc.'s 2032 outlook centres on $1.21, within a $0.7404 to $2.10 range. That is up +25% on the projected 2031 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BCDA could reach as high as $2.11, with a base case around $1.18 and support toward $0.7022 — roughly +42% from $0.8312. Momentum favours further upside here.
Expect BCDA to range from $0.6764 to $2.15 through 2034. The $1.17 average target implies a +41% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BCDA price prediction for 2035 points to an average of $1.13 (low $0.6312, high $2.11) — a potential gain of +36% on today's $0.8312. Momentum favours further upside here.
In 2040, BCDA is projected to trade between $0.7732 and $3.24, averaging $1.59 — a potential gain of +91% from today's $0.8312. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioCardia, Inc.'s 2050 outlook centres on $3.20, within a $1.44 to $7.36 range. That is up +101% on the projected 2040 average. That marks a +285% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BCDA today (≈ 1,203.079885 BCDA) could be worth
$3,851.47
+$2,851.47 (+285%) by 2050 · US Dollar
Based on the average projected BCDA price of $3.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCDAwould be worth at today's price.
$1,000 invested in BCDA on Jul 31, 2025 (≈ 467.289697 BCDA) would be worth
$388.41
-$611.59 (-61.2%) today · 0.39× · US Dollar
Based on a BCDA entry price of $2.14 vs. today's $0.8312.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.85 | $977.88 | -2.2% |
| 1 month ago | $1.19 | $698.49 | -30.2% |
| 3 months ago | $1.11 | $748.83 | -25.1% |
| 6 months ago | $1.21 | $686.94 | -31.3% |
| 1 year ago | $2.14 | $388.41 | -61.2% |
| All time (5.0y) ago | $52.35 | $15.88 | -98.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCDA forecast.
Our base-case forecast reaches $1.70 around 2050.
Implied market cap at $1.70: $25.3M
Across the multi-year horizon, the forecast shifts from neutral in the near term to bullish in the longer term. In 2032 the average price is projected at $1.19 with a max of $2.19 and a strong 47.3 ROI, followed by 2033 at an average of $1.12 and a max of $2.13 with 39.1 ROI. Through 2034 and 2035, the averages sit near $1.14 and $1.08 respectively with sizable upside (2034 max $2.21, 2035 max $2.15) and bullish sentiment.
The 2040 projection points to an average of $1.53 and a max of $3.34, ROI 89.5, with sentiment BULLISH, and by 2050 the forecast shows an average of $3.14 and a max of $7.23, ROI 288.7, maintaining a bullish stance.
2026 remains near the current price with an average of $0.8083 and a neutral outlook, but the forecast envisions meaningful upside in the long run, albeit with notable downside risk in earlier years (for example, 2030’s average of $0.6944 and ROI -14.1). These are estimates and not guarantees; actual results will depend on clinical outcomes, regulatory progress, and market conditions.
Tap a question to reveal the answer.
The 2026 forecast shows min $0.80, avg $0.8083, max $1.26 with ROI 0 and sentiment NEUTRAL.
Forecast sentiment is NEUTRAL for 2026 and 2027 through 2031, turning BULLISH from 2032 onward, with notable upside potential through 2050 (avg $3.14, max $7.23; ROI 288.7).
Yes. In 2032 the max is $2.19, in 2033 $2.13, and in 2034 $2.21, with 2032 ROI 47.3, 2033 ROI 39.1, and 2034 ROI 40.9.
By 2050, the average price is forecast at $3.14 with a max of $7.23 and ROI 288.7, with sentiment BULLISH.
The 30-day range is $0.5716 to $1.14, with current price $0.8083 and near-term support at $0.80 and resistance at $1.24, reflecting a bearish near-term bias.
BioCardia, Inc. Community Discussion
0Share your BioCardia, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.